Background: The pathogenesis driving the formation of abdominal aortic aneurysms continues to be poorly understood. Therefore, we systemically define the cytokine and circulating immune cell environment observed in human abdominal aortic aneurysm compared with risk-factor matched controls. Methods: From 2015 to 2017, a total of 274 patients donated blood to the Indiana University Center for Aortic Disease. Absolute concentrations of circulating cytokines were determined, using enzyme-linked immunosorbent assays while the expression of circulating immune cell phenotypes were assayed via flow cytometric analysis. Results: Human abdominal aortic aneurysm is characterized by a significant depletion of the antigenspecific, CD4
hemorrhagic shock, and probable death. 3 Currently, the accepted treatment paradigm consists of regimented imaging until a crosssectional aortic diameter of 5.5 cm is reached-at this point, the risk of rupture and death exceeds the high morbidity associated with surgical reconstruction. 4 Recent research has focused heavily on elucidating the pathogenesis and mechanism of AAA formation, with hopes of developing a new pharmaceutical option to arrest aneurysm growth and prevent the need for surgical intervention. [5] [6] [7] [8] [9] Previous studies have established that the histologic environment of the native aorta undergoing the transition to an aneurysmal state is characterized by an infiltration of mononuclear cells such as T and B lymphocytes, neutrophils, macrophages (M φs), and mast cells. [10] [11] [12] Unfortunately, the inciting event and mechanism that drives ectatic transformation remains a mystery. In this report, we present a descriptive analysis of the inflammatory and regulatory circulating immune environments of a large cohort of AAA patients and compare it with risk-factor matched (RFM) controls.
Methods

Separation of whole blood
The protocols presented herein are HIPAA compliant and were approved by the Indiana University Institutional Review Board (IRB #1408881234). After we acquired written informed consent, we collected whole blood from 274 subjects during a span of 2 years to be banked at the Indiana University Center for Aortic Disease (IUCAD). Potential subjects were obtained from individuals presenting for their US Preventative Task Force-recommended AAA duplex screening appointments or from previously diagnosed patients presenting for follow-up in the vascular surgery clinic. 13 Patients who screened negative by ultrasound (diameter < 30 mm) at their vascular lab appointments were deemed a RFM control for the purposes of this study.
All whole blood samples were processed within 24 hours of collection, using previously described Ficoll (GE Healthcare, Little Chalfont, UK) density centrifugation protocols with the assistance of Accuspin gradient tubes (Sigma, St. Louis, MO, USA) to isolate both peripheral blood mononuclear cells (PBMC) and plasma. 14 Plasma samples were stored in small aliquots at -80 °C to minimize freeze-thaw cycles; PBMCs were stowed in liquid nitrogen suspended in fetal bovine serum (Sigma) plus 20% dimethyl sulfoxide (Sigma) in units of 10 6 cells.
Inflammatory and regulatory cell phenotyping
Cell staining for flow cytometric analysis using antibodies specific to identifying cell markers was performed per manufacturer's instructions 
Determination of circulating cytokine concentrations
Circulating inflammatory and regulatory cytokine concentrations were determined using commercially available enzymelinked immunosorbent assays (ELISA) kits (R&D Systems, Minneapolis, MN, USA) and performed per manufacturer's instructions. For all protocols, absorbance was measured at a wavelength of 450 nm and absolute concentrations were calculated with the assistance of a 4-parameter standard curve.
Determination of plasma antibody concentrations
Human elastin fragments (ELNf) were generated by in vitro digestion with MMP-2 and MMP-9 (Sigma) per manufacturer's instructions. Relative antibody concentrations specific to human collagen V (COLV) and ELNf were assayed via a previous described modified ELISA protocol. 15 In short, respective antigenic peptides were dissolved in phosphate-buffered saline (PBS) to a stock working solution of 25 μg/mL. This stock solution was used to coat a high-protein binding 96-well polystyrene plate (Sigma) for 2 hours at 37 °C or overnight at 4 °C. Copious washings were performed between all steps with PBS-T (Tween 20, Sigma). The 96-well plate was blocked with 1% bovine serum albumin (BSA, Sigma) for 2 Baseline medications of the blood donors to the IUCAD biorepository by cohort. ACEi , angiotensin-converting enzyme inhibitor; ARB , angiotensin receptor blocker.
hours at 37 °C or overnight at 4 °C. Plasma samples were then sequentially diluted up to 1:10 0 0 to determine optimal concentrations and incubated for 2 hours at 37 °C or overnight at 4 °C. A goat antihuman IgG Fc antibody conjugated to horseradish peroxidase (HRP, Sigma) was utilized as a secondary antibody per manufacturer's recommended dilution for a duration of 1 hour at 37 °C. Reactions were performed using a 1-step TMB turbo substrate (Sigma) for 30 minutes before a 1 M sulfuric acid stop solution was added. Absorbance at 450 nm was measured within 30 minutes to calculate relative self-antibody concentrations.
Results
Demographics and comorbidities
A total of 274 patients with AAA ( n = 153) or deemed RFM controls ( n = 121) from January 2015 to September of 2017 donated blood samples to the IUCAD biorepository ( Table 1 ) . The mean aneurysm size at the time of sample collection for the AAA cohort was 49.4 mm (median = 50 mm). In the RFM cohort, 52.9% of the patients had an aortic diameter of less than 20 mm at the time of blood collection. AAA patents had more comorbidities as demonstrated by significantly higher incidences of hypertension, active smoking, and coronary artery disease. These findings were corroborated by a higher Framingham risk score (35.6% vs 40.5%, P = .02). Of note, a trend toward a decrease in diabetes mellitus was noted in the AAA group compared with the RFM controls. Baseline medications prescribed for the blood donors at the time of collection are noted in Table 2 . 
Cell phenotype expression
We observed trends toward increased expression of Th17 (3.2% vs 4.2%, P = .22) and inflammatory M φs (2.0% vs 3.0%, P = .30), but there were no differences in circulating activated and resident M φs between RFM and AAA subjects ( Fig 1 ) . With respect to the regulatory immune cells, we observed a severe depletion of the Tr1 lymphocyte in the AAA population (6.5% vs 1.4%, P < .01). Similarly, while no disparity was observed in the FOXP3 Tregs, a strong trend toward a depletion effect was noted in the alternatively stained CD127 lo Tregs (2.6% vs 1.5%, P = .06). However, Tr1 and Treg depletion was balanced by an increase in the MDSC population in the AAA patients (2.2% vs 5.8%, P < .01). Finally, no variance was noted with respect to the B10 population between cohorts.
Plasma cytokine concentration
AAA patients overexpressed the inflammatory cytokines OPN (7.0 vs 9.4 ng/mL, P = .05), IL-6 (2.3 vs 4.8 pg/mL, P < .01), and IL-17 (11.7 vs 27.7 pg/mL, P < .01). Additionally, strong trends toward higher expression of IFN-γ (12.0 vs 20.2 pg/mL, P = .14) and IL-23 (64.7 vs 142.6 pg/mL, P = .06) were also noted ( Fig 2 ) . In contrast, the plasma concentration of the regulatory cytokine TGF-β ( Fig 3 ) was elevated in the AAA condition (111.1 vs 183.2 pg/mL, P = .05). Finally, we observed a depletion of the regulatory cytokine IL-10 in the AAA population compared to the RFM controls (11.8 vs 6.8 pg/mL, P < .01), corresponding to the loss of its main secretor, the Tr1 lymphocyte. 
Antigen and antibodies concentrations
We found no changes in the circulating concentrations of ELNf (13.5 vs 14.0 ng/mL, P = .86) and COLV (0.65 vs 0.55 ng/mL, P = .10) antigens between cohorts ( Fig 4 ) . Although no disparity was noted when COLV antigen from either the RFM or AAA cohorts were compared with healthy volunteers, ELNf antigen in both cohorts were elevated when compared with the same volunteers (10.0 ng/mL, P < .05 respectively). Additionally, no difference in IgG spe-cific to COLV ( αCOLV) (0.42 vs 0.40 RUs, P = .77) was noted between the plasma of RFM and AAA patients. However, IgG specific to ELNf ( αELNf) was significantly increased in the AAA condition (0.19 vs 0.08 RUs, P = .02).
Discussion
The early events observed in the pathway to aneurysm formation include the initiation of chronic inflammation, runaway proteolysis, increased oxidative stress, and loss of the extracellular matrix. 1 This combination of events leads to aortic ectasia followed by progressive dilation. In this early stage of AAA formation, the aortic wall is characterized by an infiltration of CD4 + T cells, B cells, and macrophages. 12 In this setting, B cells and macrophages function as antigen-presenting cells (APC) and stimulate heavy depositions of immunoglobulins, suggesting an antigen-specific response to the aortic wall. 3 Interestingly, AAA shares many distinct characteristics observed in autoimmune diseases such as a predisposition to one organ; genetic susceptibility; and persistent, lingering inflammation. Recently, masses of CD4 + T cells located in the periadventitial vascular-associated lymphatic tissue were found to be expressing identical T cell receptors against an unknown antigen present in the aortic wall and therefore clonally expanded. 16 Our current hypothesis is that aneurysm formation can be divided into the (1) sensitization, (2) and inflammation stages. In the sensitization phase, elastin is broken down to small fragments, most likely by exposure to cigarette smoke and endogenous matrix metalloproteinases (MMPs), explaining the high risk of AAA formation in those with a significant pack-year history. 17 Both MMP-2 and MMP-9 have been shown to be profoundly elevated in the serum and aortic wall of aneurysmal patients compared with controls. 18 However, the inhibition of these proteases using doxycycline has largely been unsuccessful at reducing aneurysm growth in large trials. 5, 19 In our results, we describe the elevation of ELNf in both the RFM and AAA populations, both of which are characterized by heavy tobacco use. However, only the AAA patients generate an inflammatory response in the form of self-recognizing ELNf antibodies. The same elastin fragments have previously been shown to be increased in patients with tobacco-associated chronic obstructive pulmonary disease (COPD). 15 Additionally, animal models of COPD have demonstrated an ability of ELNf to perpetuate inflammation, drive disease progression, and polarize naïve monocytes toward the M1 pro-inflammatory M φs sensitized to elastinrich tissues. 20 Interestingly, Dale et al 21 inhibited these M1 M φs in a murine AAA model and noted decreased aneurysm growth, MMP expression, and loss of elastin from the aortic wall. Similarly, COLV autoantibodies have been reported in some cases of COPD. 22, 23 However, we did not observe any increased sensitivity to this antigen in our AAA subjects.
In the patient with no faulty regulatory reaction, we believe the response characterized by the second, inflammation stage is controlled via the actions of immune-suppressing cells, such as the antigen-specific CD4 + Tr1 lymphocyte, that coexpress lymphocyte activation gene 3 (LAG3) and CD49b while secreting the potent anti-inflammatory cytokine IL-10. 24 We report a depletion of Tr1 lymphocytes in AAA corresponding with a loss of their immunosuppressive circulating secretory product, IL-10. Interestingly, there is accumulating evidence that Tr1 and Th17 inflammatory lymphocytes may derive from the same naïve T cell populationprogressively gaining IL-10 activity and polarizing toward the Tr1 cell during the resolution stages of inflammatory pathologies. [25] [26] [27] In the ongoing ARREST phase I clinical trial at our institution, patients with small AAAs are given varying dosages of autologous, anti-inflammatory mesenchymal stem cells and their circulating immune environments are characterized over time. 28 Preliminarily, we observe an increase in the Tr1:Th17 ratio with no change in the absolute numbers supporting this polarization phenomenon. We hypothesize that the ability to polarize from the Th17 to the Tr1 in the AAA patient may be compromised. Not surprisingly, a 6-fold increase in the Tr1:Th17 ratio in the RFM controls were seen. A decrease in the Tr1:Th17 ratio also seemed to be correlated to the presence of AAA, regardless of size. Based on this observation, we are currently pursuing the use the Tr1:Th17 ratio as a potential screening tool for the diagnosis of AAA.
We observed an elevation in prostaglandin E2 (PGE2) in our AAA patients. Although grouped with other anti-inflammatory cytokines in this report, PGE2 can also have an inflammatory effect in certain conditions. 29 Of particular interest, PGE2 has been demonstrated to inhibit Tr1 polarization through c-Maf suppression, which may also contribute to the Tr1 depletion observed in AAA. 27 Mechanistic Tr1 studies as a follow-up to these initial findings are underway. Our preliminary in vitro results investigating AAA-derived Tr1 cells suggest that not only is the population depleted, but it is also dysfunctional, with decreased ability to migrate toward chemoattractants, secrete IL-10 in response to stimulus, and polarize monocytes to the M2 anti-inflammatory phenotype.
In the inflammation phase, self-sensitized macrophages hone to the infrarenal aorta, a relatively weak section of a large elastic artery prone to excessive mechanical stress. 30, 31 In this local environment, B and T cells are recruited and activated by M φ APCs, setting off a cascade of events that results in additional recruitment of inflammatory subtypes. 12 We noted a trend toward increased circulating inflammatory M φs but were unable to assay them in situ. In circulation, we report an elevation of Th17 CD4 + lymphocytes corresponding to an increased expression of IL-17, suggesting an antigen-specific response. The elevation of IL-17 is a hallmark finding of many autoimmune diseases and its downregulation has been shown to be of benefit in slowing AAA growth in murine models. [32] [33] [34] The elaboration of cytokines such as IL-2, IFN-γ , and TNF-α by a predominantly Th1 mononuclear response stimulates pro-inflammatory osteopontin (OPN) elaboration from macrophages and vascular smooth muscle cells further propagating inflammation. 35, 36 IL-6, which plays a role in maturation of lymphocytes, was also significantly elevated in our AAA population. This finding has been corroborated by recent reports 37 ; additionally, blocking the IL-6R has also shown some efficacy in slowing aneurysm growth in mice. 38 This study has several limitations and the results reported should be interpreted with these in mind. The first of which is the design of this study, a retrospective query of a prospectively maintained database. Clinical data points from the medical records may be abstracted incorrectly or misrepresented, introducing the increased potential for error and bias. Additionally, this study is limited by its largely descriptive nature, but will allow for the transition to further mechanistic investigations. Finally, while both RFM and AAA patients are derived from the same initial population of individuals older than 65 years, presenting for an AAA screening ultrasound, we observed increased comorbidities in the AAA group, suggesting a more overall diseased cohort.
In conclusion, in this investigation, we report the human AAA condition is defined not only by chronic inflammation but also by aberrations in immune regulation-specifically with respect to a depletion of the antigen-specific Tr1 lymphocyte. Therefore, further investigation is required to determine the causes of these irregularities to better define the mechanism of AAA formation.
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